Latest News
Dual and Triple Agonists Explained: GLP-1, GIP and Glucagon
Obesity and diabetes medicine has moved a long way from the single-hormone era. Dual and triple agonists are engineered molecules that switch on two or three hormone receptors at once. They now dominate the late-stage pipeline, and the highest doses tested have...
Latest News
Ziltivekimab ZEUS Trial: What the Null Result Means
The ziltivekimab ZEUS trial has produced one of the more instructive negative results in recent cardiovascular medicine. Novo Nordisk announced headline results on 31 July 2026 showing that its once-monthly interleukin-6 inhibitor ziltivekimab lowered inflammation...
How the Gut-Brain-Metabolism Axis Is Reshaping Targeted Therapy
For decades, the fields of oncology, neuroscience, and microbiology operated in distinct silos within therapeutic research and clinical practice. Modern drug discovery, however, is rapidly witnessing a paradigm shift toward systemic biology. Researchers increasingly...
Singapore Radiopharmaceutical Market: How H2 2026 Looks
The Singapore radiopharmaceutical market enters the second half of 2026 with more clinical capacity, more research output and a heavier regulatory calendar than at any previous point. New imaging infrastructure came online at the end of 2025, first-in-human data from...
Why True Health Foods Need Evidence, Not Fashion
Functional foods have entered the mainstream, but adding a recognised ingredient is not the same as creating a credible product. A cardiologist argues that the category’s next phase will be won on scientific rationale, dose and honest communication, not on the length...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
How Clinical Research Is Transforming the Future of Sarcoma Care
Rare cancers present one of the greatest challenges in modern oncology. Individually uncommon but collectively accounting for around one in five cancer diagnoses worldwide, they have historically attracted less research funding, fewer clinical trials and limited...
Weekly News Roundup | 03 August 2026
Life science news 3 August 2026: argenx pays $2.2 billion for what it calls a first-in-class anti-CD122 antibody, Johnson & Johnson strikes agreements worth up to $3.5 billion with in vivo CAR-T developer Sail Biomedicines, and GSK launches a £1.9 billion savings...
Personalized Cancer Care: How the Immune System is Reshaping Oncology
Immuno-oncology is not a new frontier, and for years, therapies like checkpoint inhibitors have reshaped how we treat certain cancers. While early approaches established that the immune system could fight cancer, the field has seen both major breakthroughs and clear...
FDA PreCheck Program: Seven Companies Chosen to Reshape US Manufacturing
The United States Food and Drug Administration has selected seven pharmaceutical and biotechnology companies for its FDA PreCheck Program, a pilot initiative designed to accelerate the establishment of new domestic drug manufacturing facilities. Announced on 7 August...
Retatrutide Phase 3 Data: Record Weight Loss, Unanswered Questions
Retatrutide, Eli Lilly’s investigational triple hormone receptor agonist, has now reported positive results across five Phase 3 trials. In the pivotal TRIUMPH-1 obesity study, participants on the highest dose lost an average of 28.3% of their body weight at 80 weeks,...
Responsible AI in Healthcare: Building Trust for Clinical Innovation
Artificial intelligence (AI) is rapidly transforming healthcare, moving beyond research laboratories into hospitals, clinics, and public health systems worldwide. Today, AI supports clinicians in areas such as medical imaging, clinical documentation, decision support,...
FDA Drug Approval Decisions
Last updated 31 July 2026. Covering target action dates from August to December 2026. The closing stretch of the third quarter has become the busiest regulatory window of 2026. Between early August and the end of September, the US Food and Drug Administration faces...
Clinical Trials Roundup | 31 July 2026
An FDA advisory committee votes against Capricor Therapeutics' deramiocel in Duchenne muscular dystrophy cardiomyopathy, Pfizer's ritlecitinib meets its co-primary endpoints in two Phase 3 nonsegmental vitiligo trials, Karyopharm Therapeutics' selinexor misses its...
The Security Blind Spot in Life Science Digitalization
The life sciences sector is in the midst of a digital transformation that most security teams were not built to handle. AI-driven drug discovery platforms, cloud-connected lab equipment, genomic databases, and real-time patient data pipelines are creating attack...
Making AI Work in a Regulated Medtech Industry
For several years, AI has been viewed as one of the biggest opportunities for the medtech sector. With an industry survey finding that 91% of leaders were enthusiastic about its potential, early conversations centred on how it could transform healthcare delivery and...
Measuring the Human Variables Healthcare Systems Continue to Miss
Healthcare organizations have never had more data available to them. Leaders monitor patient satisfaction scores, staffing ratios, productivity, quality indicators, denial rates, wait times, and length of stay. The dashboards are sophisticated, the reporting cadence...
Have We Lost the Plot? Why Life Sciences Can’t Let AI Become the Mission
It’s impossible to escape the topic of AI right now. AI hype in life sciences now dominates every boardroom, industry conference, pitch deck and earnings call. But we’ve seen this movie before. A decade ago, the topic was the cloud, and it, too, was everywhere -...
How Clinical Research Is Transforming the Future of Sarcoma Care
Rare cancers present one of the greatest challenges in modern oncology. Individually uncommon but collectively accounting for around one in five cancer diagnoses worldwide, they have historically attracted less research funding, fewer clinical trials and limited...
Weekly News Roundup | 03 August 2026
Life science news 3 August 2026: argenx pays $2.2 billion for what it calls a first-in-class anti-CD122 antibody, Johnson & Johnson strikes agreements worth up to $3.5 billion with in vivo CAR-T developer Sail Biomedicines, and GSK launches a £1.9 billion savings...
Personalized Cancer Care: How the Immune System is Reshaping Oncology
Immuno-oncology is not a new frontier, and for years, therapies like checkpoint inhibitors have reshaped how we treat certain cancers. While early approaches established that the immune system could fight cancer, the field has seen both major breakthroughs and clear...
FDA PreCheck Program: Seven Companies Chosen to Reshape US Manufacturing
The United States Food and Drug Administration has selected seven pharmaceutical and biotechnology companies for its FDA PreCheck Program, a pilot initiative designed to accelerate the establishment of new domestic drug manufacturing facilities. Announced on 7 August...
Retatrutide Phase 3 Data: Record Weight Loss, Unanswered Questions
Retatrutide, Eli Lilly’s investigational triple hormone receptor agonist, has now reported positive results across five Phase 3 trials. In the pivotal TRIUMPH-1 obesity study, participants on the highest dose lost an average of 28.3% of their body weight at 80 weeks,...
Responsible AI in Healthcare: Building Trust for Clinical Innovation
Artificial intelligence (AI) is rapidly transforming healthcare, moving beyond research laboratories into hospitals, clinics, and public health systems worldwide. Today, AI supports clinicians in areas such as medical imaging, clinical documentation, decision support,...
FDA Drug Approval Decisions
Last updated 31 July 2026. Covering target action dates from August to December 2026. The closing stretch of the third quarter has become the busiest regulatory window of 2026. Between early August and the end of September, the US Food and Drug Administration faces...
Clinical Trials Roundup | 31 July 2026
An FDA advisory committee votes against Capricor Therapeutics' deramiocel in Duchenne muscular dystrophy cardiomyopathy, Pfizer's ritlecitinib meets its co-primary endpoints in two Phase 3 nonsegmental vitiligo trials, Karyopharm Therapeutics' selinexor misses its...
The Security Blind Spot in Life Science Digitalization
The life sciences sector is in the midst of a digital transformation that most security teams were not built to handle. AI-driven drug discovery platforms, cloud-connected lab equipment, genomic databases, and real-time patient data pipelines are creating attack...
Making AI Work in a Regulated Medtech Industry
For several years, AI has been viewed as one of the biggest opportunities for the medtech sector. With an industry survey finding that 91% of leaders were enthusiastic about its potential, early conversations centred on how it could transform healthcare delivery and...
Measuring the Human Variables Healthcare Systems Continue to Miss
Healthcare organizations have never had more data available to them. Leaders monitor patient satisfaction scores, staffing ratios, productivity, quality indicators, denial rates, wait times, and length of stay. The dashboards are sophisticated, the reporting cadence...
Have We Lost the Plot? Why Life Sciences Can’t Let AI Become the Mission
It’s impossible to escape the topic of AI right now. AI hype in life sciences now dominates every boardroom, industry conference, pitch deck and earnings call. But we’ve seen this movie before. A decade ago, the topic was the cloud, and it, too, was everywhere -...
Featured Articles
Further News
Biotech IPO 2026: From Drought to Record-Breaking Deals
The first half of 2026 has delivered a decisive answer to a question the life sciences industry has been asking for years: is the biotech IPO window finally open again? The drought bottomed out in 2025, when fewer biotechs went public than in any year in at least half...
Want the FDA to Make Peptides More Accessible?
As the FDA considers reclassifying seven popular peptides, experts say the decision could change how patients access these compounds. As the FDA evaluates whether several commonly used peptides should become eligible for pharmacy compounding, the outcome could...
The Scientist in the Loop: Why Biopharma R&D Still Needs Human Judgment
Two years into the biopharma industry's most sustained experiment with artificial intelligence, the honest answer to "what has changed" is not the one most conference keynotes suggest. It is not that biopharma AI now runs the laboratory. It is that AI has become very...
How Can We Protect a Failing Heart Using Your Own Mini-Hearts?
Cardiovascular disease in Australia claims one life every 12 minutes. The irreversible damage to the heart is known as heart failure, a condition that progressively prevents the heart from providing the proper amount of blood to our body. This means that patients will...
Early Recognition of Actinic Keratosis in an Aging Population
Healthy aging has changed dramatically over the past several decades. Preventive medicine has expanded well beyond treating disease to identifying health risks before they become serious problems. Today, patients routinely discuss blood pressure, cholesterol,...
Psychedelic Medicine Commercialization: Altered Perceptions
Lilly’s acquisition of AtaiBeckley validates the therapeutic and economic promise of rapid-acting neuroplastogens. It also raises a harder question: can commercial teams redesign the beliefs surrounding these medicines as effectively as scientists are redesigning the...
Safety, Toxicology, and Risk Assessment of Essential Oils
Essential oils are complex mixtures of volatile phytochemicals that have long been incorporated into traditional medicine, personal care products, aromatherapy, and topical therapeutic formulations. Their diverse biological activities—including antimicrobial,...
Weekly News Roundup | 27 July 2026
Life science news 27 July 2026: GSK wins its first lung cancer approval with a selective ROS1 inhibitor, Lilly's triple agonist retatrutide delivers up to 22.6 per cent weight loss in two pivotal trials, and the MHRA clears what it calls the world's first lower-carbon...
The Preclinical Bottleneck: Why Traditional Antibody Discovery Hits a Wall
The therapeutic landscape has been undeniably transformed by monoclonal antibodies (mAbs). From oncology to autoimmune disorders and emerging infectious diseases, mAbs represent one of the most powerful modalities in modern medicine. However, the initial phase of...
Exploring the Role of Astrocytes in MND With Translatable Human Cell Models
Motor Neuron Disease (MND) is characterised by the progressive loss of motor neurons. Despite years of research into the disease, effective treatments remain extremely limited and half of patients pass away within two years of diagnosis. To date there is no cure for...
Clinical Trials Roundup | 24 July 2026
Merck's enlicitide receives FDA approval as the first oral PCSK9 inhibitor for adults with hypercholesterolaemia, GSK's zidesamtinib earns FDA approval as a next-generation ROS1 selective inhibitor for previously treated non-small cell lung cancer, GSK's camlipixant...
New Platform Pairly’s Rapid Growth Highlights Urgent Need to Simplify UK Social Care
An entrepreneur whose father died before care at home could be arranged has built a digital platform that is transforming how families find care across the UK. After experiencing first-hand how difficult it was to arrange support for his own father, Pairly co-founder...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.